Patents by Inventor Matthew Buck

Matthew Buck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING CANCERS WITH ALKYNE SUBSTITUTED QUINAZOLINE DERIVATIVES
    Publication number: 20240075042
    Abstract: The present disclosure relates to methods of treating or preventing cancer (e.g., advanced solid cancer) using Compound No. 1 or Compound No. 2: or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.
    Type: Application
    Filed: November 2, 2021
    Publication date: March 7, 2024
    Inventors: Elizabeth BUCK, Matthew O'CONNOR, Darlene ROMASHKO, Tai-An LIN, Alexander FLOHR, Luca ARISTA, Iwona WRONA, Matthew LUCAS, Chris ROBERTS, Giorgio OTTAVIANI, Sherri SMITH, Nigel WATERS
  • Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
    Patent number: 7939662
    Abstract: The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 10, 2011
    Assignee: Apotex Pharmachem Inc.
    Inventors: Carlos Zetina-Rocha, Allan W. Rey, Matthew A. Buck, Lotfi Derdour, Stephen E. Horne, Keshava K. S. Murthy
  • Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
    Publication number: 20090030204
    Abstract: The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof.
    Type: Application
    Filed: December 6, 2007
    Publication date: January 29, 2009
    Inventors: Carlos Zetina-Rocha, Allan W. Rey, Matthew A. Buck, Lotfi Derdour, Stephen E. Horne, K.S. Keshava Murthy
  • Process for the Preparation of Ziprasidone (5-[2-[4-(1,2-Benziosothiazol-3-Y1)-1-Piperazinyl]Ethyl]-6-Chloro-1,3-Dihydro-2H-Indol-2- One
    Publication number: 20070265447
    Abstract: The present invention provides a new and useful process for preparing 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3dihydro-2H-indol-2-one (ziprasidone) and methods for its purification. The process comprises the steps of: (i) mixing 6-chloro-5-(2-chloroethyl)-1,3-dihydro-2H-indol-2-one with either a free base or salt form of 3-(1-piperazinyl)-1,2-benzoisothiazole, in the presence of an alkaline compound and a high-boiling polar organic solvent or mixture of high boiling polar organic solvents, (ii) heating the mixture and stirring for a sufficient amount of time to obtain ziprasidone formation, (iii) cooling the mixture, adding it to water and filtering off the product, (iv) adding water to the product and stirring the suspension, and (v) isolating crude ziprasidone.
    Type: Application
    Filed: November 4, 2005
    Publication date: November 15, 2007
    Inventors: Carlos Zetina-Rocha, Allan Rey, Stephen Horne, Matthew Buck
  • Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1, 3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
    Publication number: 20050256139
    Abstract: The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof.
    Type: Application
    Filed: July 7, 2004
    Publication date: November 17, 2005
    Inventors: Carlos Zetina-Rocha, Allan Rey, Matthew Buck, Lotfi Derdour, Stephen Horne, Keshava Murthy